Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Amicus Therapeutics Company Profile (NASDAQ:FOLD)

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $10.75 (5.62% downside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
Show:
DateFirmActionRatingPrice TargetActions
5/8/2015ZacksDowngradeBuy -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/19/2015Leerink SwannSet Price TargetBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015Leerink SwannBoost Price TargetOutperform$9.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2015Janney Montgomery ScottInitiated CoverageBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2014JPMorgan Chase & Co.Boost Price TargetOverweight$8.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/20/2014Cowen and CompanyBoost Price Target$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2014Janney Montgomery ScottUpgradeNeutral -> Buy$2.50 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2014Leerink SwannUpgradeMarket Perform -> Outperform$2.50 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2014JPMorgan Chase & Co.UpgradeNeutral -> OverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2014Leerink SwannLower Price Target$3.00 -> $2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014Leerink SwannBoost Price Target$2.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/21/2013Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/21/2013JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/24/2013Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/22/2013 forward)